EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study

A van Ommen-Nijhof, T G Steenbruggen, T G Wiersma, S Balduzzi, A Daletzakis, M J Holtkamp, M Delfos, M Schot, K Beelen, E J M Siemerink, J Heijns, I A Mandjes und 5 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.115083 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von A van Ommen-Nijhof und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Thiotepa. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsThiotepaHumansFemaleMiddle AgedAdultAgedHomologous RecombinationCyclophosphamideNeoplasm MetastasisCarboplatinAntineoplastic Agents, AlkylatingQuality of Life

Stichwörter der Autor:innen

Homologous recombination deficiencyIntensified alkylating chemotherapyMultimodality treatmentOligometastatic breast cancer

Substanzen

ThiotepaCyclophosphamideCarboplatinAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands.
  • Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of internal medicine, St Antonius hospital, Nieuwegein, the Netherlands.
  • Department of radiotherapy, NKI-AVL, Amsterdam, the Netherlands.
  • Department of biometrics, NKI-AVL, Amsterdam, the Netherlands.
  • Department of internal medicine, Rijnstate, Arnhem, the Netherlands.
  • Department of internal medicine, Ziekenhuisgroep Twente, Almelo, Hengelo, the Netherlands.

Förderung

  • Dutch Cancer Society

Zitieren

APA

van Ommen-Nijhof, A., Steenbruggen, T. G., Wiersma, T. G., Balduzzi, S., Daletzakis, A., Holtkamp, M. J., Delfos, M., Schot, M., Beelen, K., Siemerink, E. J. M., Heijns, J., Mandjes, I. A., Wesseling, J., Rosenberg, E. H., Vrancken Peeters, M. J. T., Linn, S. C., & Sonke, G. S. (2024). Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115083

Vancouver

van Ommen-Nijhof A, Steenbruggen TG, Wiersma TG, Balduzzi S, Daletzakis A, Holtkamp MJ, et al. Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115083

BibTeX
@article{vanOmmenNijhof2024,
  author = {van Ommen-Nijhof, A and Steenbruggen, T G and Wiersma, T G and Balduzzi, S and Daletzakis, A and Holtkamp, M J and Delfos, M and Schot, M and Beelen, K and Siemerink, E J M and Heijns, J and Mandjes, I A and Wesseling, J and Rosenberg, E H and Vrancken Peeters, M J T and Linn, S C and Sonke, G S},
  title = {Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.115083}
}
Kostenlos starten →